Zymeworks Inc. ZYME
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -0.72%
- 1 year
- +9.74%
5D -1.31 (-4.77%)
- Market cap
- 1.81B
- Revenue (ttm)
- 265.97M
- Profit margin
- 16.28%
- EPS (ttm)
- 0.53
- Shares out
- 68.70M
- P/E ratio
- 49.32
- Forward P/E
- 54.95
- YTD return
- -0.72%
- 1-year return
- +9.74%
- 50-day average
- 27.21
- Volume
- 738.81K
- Avg volume
- 1.09M
- Open
- 26.30
- Previous close
- 26.86
- Day's range
- 26.09 – 27.56
- 52-week range
- 21.52 – 31.97
- Beta
- 1.30
- Analysts
- Strong Buy
- Price target
- 43.29 (+65.6%)
- Earnings date
- Mar 1, 2027
Key statistics
- 200-day average
- 25.59
- Enterprise value
- 1.81B
- Price / sales
- 6.80
- Price / book
- 7.21
- Revenue growth
- 828.70%
- Free cash flow
- -195.69M
- Total cash
- 100.46M
- Total debt
- 53.13M
- Return on equity
- 14.98%
- Short % of float
- 12.89%
Fundamental scorecard
8 of 25 checks passed on ZYME’s reported financials
8of 25 checks passed
- Value 1 of 5
- Growth 3 of 5
- Profitability 2 of 5
- Financial health 2 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 35.00
- Target (mean)
- 43.29
- Target (high)
- 60.00
- Strong buy2
- Buy12
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 1, 2027
Expected Mar 1, 2027. Consensus EPS estimate 2.19.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 1, 2027 | Dec 30, 2026 | 0.1257 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | 2.27 | 2.28 | +0.01 | +0.44% |
| Aug 6, 2026 | Jun 30, 2026 | -0.57467 | -0.62 | -0.05 | -7.89% |
| May 7, 2026 | Mar 31, 2026 | -0.10 | -0.59 | -0.49 | -490.00% |
| Mar 2, 2026 | Dec 31, 2025 | -0.35 | -0.55 | -0.20 | -57.14% |
| Nov 6, 2025 | Sep 30, 2025 | -0.30 | -0.26 | +0.04 | +13.33% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | Citigroup | main | Buy | Buy |
| Nov 10, 2026 | TD Cowen | main | Buy | Buy |
| Nov 10, 2026 | Truist Securities | main | Buy | Buy |
| Nov 10, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Oct 28, 2026 | Truist Securities | main | Buy | Buy |
| Oct 7, 2026 | Truist Securities | main | Buy | Buy |
About Zymeworks Inc.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zymeworks.com
News
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks (NASDAQ:ZYME) Shares Gap Up Following Analyst Upgrade
Zymeworks Announces $200 Million Share Repurchase Authorization Citizens Maintains Market Outperform on Zymeworks, Raises Price Target to $39
Citigroup Maintains Buy on Zymeworks, Raises Price Target to $44
TD Cowen Maintains Buy on Zymeworks, Raises Price Target to $39
Truist Securities Maintains Buy on Zymeworks, Raises Price Target to $36
HC Wainwright & Co. Maintains Buy on Zymeworks, Raises Price Target to $56
Zymeworks Raises FY2026 Sales Guidance from $278.000M-$292.000M to $337.000M-$351.000M vs $302.672M Est
Zymeworks Q3 EPS $2.28 Beats $2.18 Estimate, Sales $256.460M Beat $228.465M Estimate
Your note
Sign in to keep a note on ZYME — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CIONGOLI GREGORY AUSTIN | Director | Stock Award(Grant) | Aug 11, 2025 | 493,500 |
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jun 25, 2025 | 0 |
| GALBRAITH KENNETH HARRY | Chief Executive Officer | Sale | Jan 11, 2026 | 226,842 |
| HOLLYWOOD MARK | Chief Operating Officer | Stock Award(Grant) | Jul 5, 2026 | 133,852 |
| MOORE PAUL ANDREW | Officer | Sale | Nov 12, 2026 | 33,756 |
| PATTERSON LEONE D. CPA | Chief Financial Officer | Stock Award(Grant) | Jan 5, 2026 | 459 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 36.46% | 22,970,388 | 600.45M | Sep 29, 2026 |
| Rubric Capital Management LP | 11.11% | 7,000,000 | 182.98M | Sep 29, 2026 |
| Blackrock Inc. | 6.69% | 4,212,745 | 110.12M | Sep 29, 2026 |
| Perceptive Advisors Llc | 5.63% | 3,545,501 | 92.68M | Sep 29, 2026 |
| BVF Inc. | 5.50% | 3,464,142 | 90.55M | Sep 29, 2026 |
| Morgan Stanley | 5.14% | 3,236,915 | 84.61M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.39% | 1,508,613 | 39.44M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.88% | 1,185,928 | 31.00M | Sep 29, 2026 |
| IVY FUNDS-Nomura Small Cap Growth Fund | 0.95% | 600,846 | 15.71M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.85% | 538,110 | 14.07M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.82% | 514,484 | 13.45M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.68% | 425,949 | 11.13M | Sep 29, 2026 |
